Page 12 - Read Online

Tong et al. Hepatoma Res 2019;5:36 I http://dx.doi.org/10.20517/2394-5079.2019.005 Page 7 of 13

Table 2. Bivariate predictors of tumor growth rate
n Median TGR (%/mo) Q1-Q3 (%/mo) P-value
Gender
Female 58 15.6 4.60-35.9 0.6560
Male 106 19.3 4.90-40.4
Ethnicity
African American 6 9.10 0.70-19.3 0.2526
Asian 105 18.0 5.40-38.4
Hispanic 23 11.8 2.40-34.4
White 30 26.3 6.00-47.9
Virology
HBV 65 23.2 5.40-42.4 0.3284
HCV 98 16.6 4.10-33.4
HBV + HCV 1 2.20 --
HBV genotype
A 3 33.0 4.60-59.6 0.5253
B 10 17.9 3.30-38.5
C 19 21.8 9.60-51.7
F 1 -- --
HBV precore mutation
Yes 15 28.7 8.10-54.0 0.4053
No 18 22.5 11.3-76.8
HBV basal core promoter mutation
Yes 20 22.5 10.3-50.4 0.7229
No 8 17.8 6.30-41.1
HBeAg
Negative 42 20.5 4.90-37.8 0.3877
Positive 14 30.8 7.70-68.5
HBV DNA
Negative 3 42.4 5.30-64.9 0.7686
Positive 54 21.1 5.20-35.6
HCV genotype
1 45 12.9 2.30-28.1 0.1408
2 17 22.0 9.20-42.3
3 6 29.3 23.5-44.3
6/7/mixed 9 3.00 2.20-32.5
HCV RNA
Negative 15 14.4 4.70-26.2 0.3802
Positive 61 15.2 3.10-28.5
Antiviral treatment
Yes 50 18.6 2.30-37.8 0.8826
No 108 17.8 7.10-36.8
Albumin (g/dL)
≤ 3.50 55 27.0 8.00-46.3 0.0161
> 3.50 109 14.2 2.60-32.5
AFP (ng/mL)
≤ 10.0 54 11.1 2.50-28.3 0.0294
10.0-191 66 18.7 7.40-34.8
> 191 40 30.3 4.20-75.2
3
3
Platelet count (× 10 mm )
≤ 75.0 34 23.7 7.70-39.5 0.2834
75.0-150 62 15.4 2.50-31.7
> 150 64 20.4 7.10-41.8
Surveillance
Yes 113 18.0 4.30-38.4 0.5565
No 51 15.2 5.00-37.6
Diabetes
Yes 32 10.5 2.00-28.1 0.0506
No 125 21.6 5.60-42.3
Cirrhosis